Neoplasm Invasiveness / Pancreatic Neoplasms / Cell Line, Tumor · Journal article

UBE2C promotes pancreatic cancer progression through PI3K/Akt/mTOR signaling pathway.

Cell Cycle · May 19, 2026

Preliminary Why this matters to you Expert discussion

Early or partial results. Treat as a signal, not a conclusion.

AI Summary

This bioinformatic and in vitro study identifies UBE2C as elevated in pancreatic cancer tissues and associated with poor prognosis (poorer differentiation, later T stage, and worse overall and disease-free survival), and demonstrates that UBE2C knockdown reduces pancreatic cancer cell proliferation, migration, and invasion through suppression of PI3K/Akt/mTOR pathway phosphorylation. Administration of the Akt activator SC79 reverses the inhibitory effects of UBE2C knockdown, supporting a causal mechanistic link. This is preclinical evidence of potential therapeutic relevance but lacks clinical trial data or quantified effect sizes.

What was studied

Bioinformatic analysis and in vitro cell line study with pathway knockdown and rescue. Pancreatic cancer cell lines and tissues from public databases; comparison to adjacent normal pancreatic tissues and normal pancreatic cells.. Intervention: UBE2C knockdown in pancreatic cancer cell lines; administration of SC79 (PI3K/Akt pathway activator) to rescue knockdown effects.. Compared with: Control cell lines (unspecified); cells with intact UBE2C expression; normal pancreatic tissues and cells..

Key findings

UBE2C expression is significantly elevated in pancreatic cancer tissues compared to adjacent tissues and normal pancreatic tissue, with elevated protein expression confirmed by HPA database. High UBE2C expression correlates with poorer differentiation grade and later T stage of pancreatic cancer based on TCGA database analysis. High UBE2C expression correlates with poorer overall survival (OS) and disease-free survival (DFS) in pancreatic cancer patients.

Safety

Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.

Who this may help

UBE2C emerges as a potential biomarker for early detection and prognostification in pancreatic cancer and a putative therapeutic target via the PI3K/Akt/mTOR axis. However, preclinical mechanism alone does not yet support clinical translation; prospective validation in patient cohorts and clinical efficacy trials are needed.

Plain-language summary

This is a mechanistic cell and tissue study demonstrating that UBE2C knockdown suppresses pancreatic cancer cell behavior through PI3K/Akt/mTOR pathway inhibition, with reversal by pathway activator SC79, but lacks clinical trial data, human efficacy endpoints, or effect sizes with confidence intervals.

Study design

As stated by the source record.

MethodsUBE2C expression analyzed in pancreatic cancer tissues and cell lines using public datasets (GSE28735, GEPIA2, HPA, TCGA, LinkedOmics). UBE2C was knocked down in pancreatic cancer cell lines; cell proliferation, migration, and invasion were measured. PI3K/Akt/mTOR pathway phosphorylation was quantified by Western blot. The pathway activator SC79 was administered to reverse the effects of UBE2C knockdown. Correlation between UBE2C expression and clinicopathological features (differentiation grade, T stage, OS, DFS) was determined from TCGA database.

DesignBioinformatic analysis and in vitro cell line study with pathway knockdown and rescue

PopulationPancreatic cancer cell lines and tissues from public databases; comparison to adjacent normal pancreatic tissues and normal pancreatic cells.

InterventionUBE2C knockdown in pancreatic cancer cell lines; administration of SC79 (PI3K/Akt pathway activator) to rescue knockdown effects.

ComparatorControl cell lines (unspecified); cells with intact UBE2C expression; normal pancreatic tissues and cells.

Reported figures

Quoted from the source exactly as published.

Pancreatic cancer incidence and mortality (global, 2020)approximately 496,000 new cases and 466,000 related deaths

5-year survival rate for resected pancreatic cancer20%-30%

Recurrence rate for resected pancreatic cancer70%-80%

Median overall survival (unresectable locally advanced or metastatic pancreatic cancer)8.5 months to 11.1 months

Clinical bottom line

Caveats

No quantified effect sizes, hazard ratios, or confidence intervals provided for survival or pathway modulation endpoints.
Cell line experiments lack explicit reporting of sample sizes, replication number, or statistical significance testing methods.
No in vivo (animal model) validation of UBE2C knockdown or therapeutic targeting reported.
Bioinformatic associations do not establish causation; reversal with SC79 is suggestive but does not exclude off-target effects or alternative mechanisms.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

limited

Bioinformatic analysis, cell line experiments, and rescue studies without randomization or blinding.

Directness

limited

Cell line and tissue expression data; no human intervention or clinical outcomes reported.

Consistency

moderate

Findings supported by multiple databases (GSE28735, GEPIA2, HPA, TCGA, LinkedOmics) and knockdown/rescue experiments.

Risk of bias

insufficient

No reporting of blinding, randomization, or control of confounders in cell experiments.

Sample adequacy

insufficient

Sample sizes for cell experiments and tissue samples not stated in provided text.

Source abstract

UBE2C, a key member of the ubiquitin-proteasome system, is overexpressed in various malignant tumors and correlates with poor prognosis. Our findings reveal that UBE2C expression is elevated in both pancreatic cancer cell lines and tissues compared to normal pancreatic cells and tissues, with this aberrant expression linked to a poor prognosis. Knockdown of UBE2C expression reduces pancreatic cancer cell proliferation, migration, and invasion, while significantly decreasing the phosphorylation of the PI3K/AKT/mTOR signaling pathway. Administration of the pathway activator SC79 reverses the inhibitory effects of UBE2C knockdown on the PI3K/AKT/mTOR pathway, restoring the proliferation, migration, and invasion of pancreatic cancer cells. These results suggest that UBE2C promotes pancreatic cancer progression via the PI3K/AKT/mTOR signaling pathway. Thus, UBE2C serves as a potential biomarker for the early detection and diagnosis of pancreatic cancer and may represent a promising therapeutic target.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Neoplasm InvasivenessZhou ZhouYuhang ChenPancreatic NeoplasmsCell Line, TumorDisease ProgressionPing Li